This website requires certain cookies to work and uses other cookies to help you have the best experience. By visiting this website, certain cookies have already been set, which you may delete and block. By closing this message or continuing to use our site, you agree to the use of cookies. Visit our updated privacy and cookie policy to learn more.
This Website Uses Cookies By closing this message or continuing to use our site, you agree to our cookie policy. Learn MoreThis website requires certain cookies to work and uses other cookies to help you have the best experience. By visiting this website, certain cookies have already been set, which you may delete and block. By closing this message or continuing to use our site, you agree to the use of cookies. Visit our updated privacy and cookie policy to learn more.
On March 17, 2023, two bipartisan pieces of legislation were introduced to the U.S. House of Representatives with the goal of requiring the U.S. Food and Drug Administration (FDA) to regulate cannabidiol (CBD) products in foods and dietary supplements.
The U.S. Food and Drug Administration (FDA) has decided that cannabidiol (CBD) products will not be regulated as a food or supplement, rather, a new approach will be developed. The agency has also denied three consumer petitions requesting that FDA allow the marketing of CBD products as dietary supplements.
A recent study has found pervasive, low levels of lead, cadmium, arsenic, mercury, and phthalates in U.S. cannabidiol products. The study also demonstrated substantial inaccuracies of product label claims for CBD potency.
The European Food Safety Authority (EFSA) announced that it cannot determine the safety of cannabidiol as a novel food, citing significant knowledge gaps and several causes for concern.